SEC Form 4 · accession 0001140361-17-026024
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Mueller
Officer — SVP, Corporate Controller
Period of report
Jun 22, 2017
Accepted (ET)
Jun 23, 2017 · 5:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 22, 2017 | M | 2,671 | $21.51 | A | 15,556 | D | |
| Common StockF1,F2 | Jun 22, 2017 | S | 2,671 | $100.00 | D | 12,885 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F3 | $21.51 | Jun 22, 2017 | M | 2,671 | D | Nov 12, 2010 | May 11, 2020 | Common Stock | 2,671 | 0 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on March 13, 2017.
- F2All shares sold at the same price.
- F3Reflects the number of options outstanding after the transactions from this specific stock option grant.